Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors

Wu, Qing; Liu, Junjin; Zhang, Yanhong; Wu, Su‐Mei; Xie, Xianhe

doi:10.1007/s00262-020-02515-w

Cited by 5 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, the significance of tumour-infiltrating lymphocytes is difficult to implement as a biomarker for ICI response due to the technical constraints of assessment methods and biopsy material representativeness. The transcriptional signatures of immune responsiveness, like a ratio of CD8 + T versus T helper 1 cell cytokine mRNA, red blood cell distribution width (30), baseline serum sodium concentration (31), blood levels of prolactin (32) and positron emission tomography (33) were used to predict the PFS and overall survival in response to ICI therapy. Despite advances in new methodologies, routine measurement of specific tumour markers remains challenging because some of them are rapidly degraded, difficult to assay and/or masked by highly abundant blood proteins like ALB, AAT, or HP.…”

Section: Discussionmentioning

confidence: 99%

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Schneider

Roży²,

Wrenger

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

In the last decade, targeting the immune system became a promising therapy in advanced lung cancer stages. However, in a clinical follow-up, patient responses to immune checkpoint inhibitors widely differ. Peripheral blood is a minimally invasive source of potential biomarkers to explain these differences. We blindly analyzed serum samples from 139 patients with non-small cell lung cancer prior to anti-PD-1 or anti-PD-L1 therapies to assess whether baseline levels of albumin (ALB), alpha-1 acid glycoprotein (AGP), alpha1-antitrypsin (AAT), alpha2-macroglobulin (A2M), ceruloplasmin (CP), haptoglobin (HP), alpha1-antichymotrypsin (ACT), serum amyloid A (SAA), and high-sensitivity C-reactive protein (hs-CRP), have a predictive value for immunotherapy success. Disease progression-free survival (PFS) was calculated based on RECIST 1.1 criteria. A multivariate Cox regression analysis, including serum levels of acute-phase proteins and clinical parameters, revealed that higher pre-therapeutic levels of HP and CP are independent predictors of a worse PFS. Moreover, a combined panel of HP and CP stratified patients into subgroups. We propose to test this panel as a putative biomarker for assessing the success of immunotherapy in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Schneider

Roży²,

Wrenger

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Their performance status (PS) was evaluated upon inclusion and re-evaluated every 4 months according to the immunotherapy criteria. The disease progression was evaluated upon inclusion and during re-staging with positron emission tomography according to the PERCIST criteria [24][25][26]. The observation of the patient was stopped when the second progression of the disease was recorded.…”

Section: Methodsmentioning

confidence: 99%

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Hohenforst-Schmidt¹,

Huang²,

Zhou³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients. Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.

show abstract

“…[ 102 ] Additionally, PET is an effective approach to predict the PFS and OS in ICI-treated NSCLC patients. [ 103 ] After further validation, these means will be indispensable in predicting ICI efficacy.…”

Section: Biomarkersmentioning

confidence: 99%

Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective

Shi

Zhao²

2020

Chinese Medical Journal

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are widely used in lung cancer therapy due to their effectiveness and minimal side effects. However, only a few lung cancer patients benefit from ICI therapy, driving the need to develop alternative biomarkers. Programmed death-ligand 1 (PD-L1) molecules expressed in tumor cells and immune cells play a key role in the immune checkpoint pathway. Therefore, PD-L1 expression is a prognostic biomarker in evaluating the effectiveness of programmed death-1 (PD-1)/PD-L1 inhibitors. Nevertheless, adverse predictive outcomes suggest that other factors are implicated in the response. In this review, we present a detailed introduction of existing biomarkers concerning tumor abnormality and host immunity. PD-L1 expression, tumor mutation burden, neoantigens, specific gene mutations, circulating tumor DNA, human leukocyte antigen class I, tumor microenvironment, peripheral inflammatory cells, and microbiome are discussed in detail. To sum up, this review provides information on the current application and future prospects of ICI biomarkers.

show abstract

Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors

Cited by 5 publications

References 37 publications

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective

Contact Info

Product

Resources

About